BACKGROUND
Allogeneic hematopoietic cell transplantation (HCT) is the only curative therapy for myelofibrosis (MF), and donor selection remains one of the few modifiable determinants of outcome. As the unrelated donor pool ages, the impact of donor age in matched unrelated donor (MUD) HCT for MF has become increasingly...
K. Sakatoku, Yutaka Shimazu, Makoto Murata et al.· Transplantation and Cellular...· 0 citations
Although recent studies suggested an enhanced graft-versus-tumor (GVT) effect with cord blood transplantation (CBT), higher rates of engraftment failure, acute graft-versus-host disease (GVHD), and infections, including cytomegalovirus (CMV), contribute to increased nonrelapse mortality (NRM). Thus, further optimizatio...
Shunto Kawamura, Y. Akahoshi, Hideaki Nakasone et al.· Transplantation and Cellular...· 0 citations
According to data from the Japanese registry managed by the Transplant Registry Unified Management Program, the number of autologous stem cell transplantations (auto-SCT) in 2018 was approximately 60% of that of allogeneic SCT (allo-SCT). The opposite trend has been reported in the United States. Thus, we hypothesized...
Y. Kuwatsuka, Kikue Sato, Y. Atsuta et al.· Blood cell therapy· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
